COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
- PMID: 34749396
- PMCID: PMC8575532
- DOI: 10.1182/bloodadvances.2021005616
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Abstract
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.
Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
